ATBPF Antibe Therapeutics Inc

USD 0.32 -0.01 -1.546551
Icon

Antibe Therapeutics Inc (ATBPF) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.3183

-0.01 (-1.55)%

USD 0.02B

750.00

USD 2.00(+528.34%)

N/A

Icon

ATBPF

Antibe Therapeutics Inc (USD)
COMMON STOCK | OTC
USD 0.32
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.02B

N/A

USD 0.32

Antibe Therapeutics Inc (ATBPF) Stock Forecast

USD 2.00
(+528.34%)

Based on the Antibe Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Antibe Therapeutics Inc is USD 2.00 over the next 12 months. Antibe Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Antibe Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Antibe Therapeutics Inc’s stock price was USD 0.3183. Antibe Therapeutics Inc’s stock price has changed by +4.12% over the past week, -56.69% over the past month and -26.49% over the last year.

No recent analyst target price found for Antibe Therapeutics Inc
No recent average analyst rating found for Antibe Therapeutics Inc

Company Overview Antibe Therapeutics Inc

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that s...Read More

https://www.antibethera.com

15 Prince Arthur Avenue, Toronto, ON, Canada, M5R 1B2

11

March

USD

USA

Adjusted Closing Price for Antibe Therapeutics Inc (ATBPF)

Loading...

Unadjusted Closing Price for Antibe Therapeutics Inc (ATBPF)

Loading...

Share Trading Volume for Antibe Therapeutics Inc Shares

Loading...

Compare Performance of Antibe Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ATBPF

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Antibe Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S -1.95 (-1.51%) USD599.92B 48.04 5.17

ETFs Containing ATBPF

Symbol Name ATBPF's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Antibe Therapeutics Inc (ATBPF) Stock

Based on ratings from 1 analysts Antibe Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on ATBPF's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for ATBPF is USD 2.00 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 2.

Unfortunately we do not have enough data on ATBPF's stock to indicate if its overvalued.

The last closing price of ATBPF's stock was USD 0.32.

The most recent market capitalization for ATBPF is USD 0.02B.

Based on targets from 1 analysts, the average taret price for ATBPF is projected at USD 2.00 over the next 12 months. This means that ATBPF's stock price may go up by +528.34% over the next 12 months.

We can't find any ETFs which contains Antibe Therapeutics Inc's stock.

As per our most recent records Antibe Therapeutics Inc has 11 Employees.

Antibe Therapeutics Inc's registered address is 15 Prince Arthur Avenue, Toronto, ON, Canada, M5R 1B2. You can get more information about it from Antibe Therapeutics Inc's website at https://www.antibethera.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...